IN2015KN00449A - - Google Patents
Info
- Publication number
- IN2015KN00449A IN2015KN00449A IN449KON2015A IN2015KN00449A IN 2015KN00449 A IN2015KN00449 A IN 2015KN00449A IN 449KON2015 A IN449KON2015 A IN 449KON2015A IN 2015KN00449 A IN2015KN00449 A IN 2015KN00449A
- Authority
- IN
- India
- Prior art keywords
- patient
- debrafenib
- trametinib
- rfs
- time period
- Prior art date
Links
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004066 trametinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of debrafenib and trametinib for a time period sufficient to increase relapse free survival (RFS).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696375P | 2012-09-04 | 2012-09-04 | |
| PCT/US2013/057432 WO2014039375A1 (en) | 2012-09-04 | 2013-08-30 | Method of adjuvant cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015KN00449A true IN2015KN00449A (en) | 2015-07-17 |
Family
ID=50237545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN449KON2015 IN2015KN00449A (en) | 2012-09-04 | 2013-08-30 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20150216868A1 (en) |
| EP (2) | EP3981408A1 (en) |
| JP (3) | JP2015527374A (en) |
| KR (1) | KR102134585B1 (en) |
| CN (2) | CN104582706A (en) |
| AU (2) | AU2013313050A1 (en) |
| BR (1) | BR112015004578A2 (en) |
| CA (1) | CA2882437C (en) |
| CY (1) | CY1124812T1 (en) |
| DK (1) | DK2892535T3 (en) |
| ES (1) | ES2900825T3 (en) |
| HR (1) | HRP20211817T1 (en) |
| HU (1) | HUE056646T2 (en) |
| IN (1) | IN2015KN00449A (en) |
| LT (1) | LT2892535T (en) |
| PL (1) | PL2892535T3 (en) |
| PT (1) | PT2892535T (en) |
| RU (1) | RU2640180C2 (en) |
| SI (1) | SI2892535T1 (en) |
| WO (1) | WO2014039375A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102134585B1 (en) | 2012-09-04 | 2020-07-17 | 노바르티스 아게 | Method of adjuvant cancer treatment |
| CN106062214B (en) | 2013-12-28 | 2020-06-09 | 夸登特健康公司 | Methods and systems for detecting genetic variation |
| JP7114575B2 (en) | 2016-09-19 | 2022-08-08 | ノバルティス アーゲー | A therapeutic combination comprising a RAF inhibitor and an ERK inhibitor |
| IL311471A (en) * | 2017-05-02 | 2024-05-01 | Novartis Ag | Combined treatment |
| WO2019204399A1 (en) * | 2018-04-17 | 2019-10-24 | The University Of Chicago | Methods and compositions for treating cancer |
| CN109106893B (en) * | 2018-11-12 | 2021-04-20 | 上海市中西医结合医院 | Traditional Chinese medicine compound preparation for regulating intestinal barrier function and preparation method thereof |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| EP4073102A4 (en) * | 2019-12-12 | 2024-05-08 | Ting Therapeutics LLC | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS |
| EP4444299A1 (en) | 2021-12-06 | 2024-10-16 | My Personal Therapeutics Ltd | A combination treatment for cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2298768T3 (en) | 2004-06-11 | 2013-03-29 | Japan Tobacco Inc | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer |
| KR101976003B1 (en) * | 2005-02-18 | 2019-05-09 | 아브락시스 바이오사이언스, 엘엘씨 | Combinations and modes of administration of therapeutic agents and combination therapy |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| PT2488033T (en) * | 2009-10-16 | 2019-09-10 | Novartis Ag | COMBINATION UNDERSTANDING A MEK INHIBITOR AND A B-RAF INHIBITOR |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| KR102134585B1 (en) | 2012-09-04 | 2020-07-17 | 노바르티스 아게 | Method of adjuvant cancer treatment |
-
2013
- 2013-08-30 KR KR1020157008387A patent/KR102134585B1/en active Active
- 2013-08-30 SI SI201331951T patent/SI2892535T1/en unknown
- 2013-08-30 ES ES13835019T patent/ES2900825T3/en active Active
- 2013-08-30 IN IN449KON2015 patent/IN2015KN00449A/en unknown
- 2013-08-30 CN CN201380046144.4A patent/CN104582706A/en active Pending
- 2013-08-30 CA CA2882437A patent/CA2882437C/en active Active
- 2013-08-30 HR HRP20211817TT patent/HRP20211817T1/en unknown
- 2013-08-30 PL PL13835019T patent/PL2892535T3/en unknown
- 2013-08-30 US US14/422,182 patent/US20150216868A1/en not_active Abandoned
- 2013-08-30 WO PCT/US2013/057432 patent/WO2014039375A1/en not_active Ceased
- 2013-08-30 EP EP21190550.0A patent/EP3981408A1/en active Pending
- 2013-08-30 AU AU2013313050A patent/AU2013313050A1/en not_active Abandoned
- 2013-08-30 LT LTEPPCT/US2013/057432T patent/LT2892535T/en unknown
- 2013-08-30 BR BR112015004578A patent/BR112015004578A2/en not_active IP Right Cessation
- 2013-08-30 EP EP13835019.4A patent/EP2892535B1/en active Active
- 2013-08-30 PT PT138350194T patent/PT2892535T/en unknown
- 2013-08-30 JP JP2015530072A patent/JP2015527374A/en active Pending
- 2013-08-30 RU RU2015105821A patent/RU2640180C2/en active
- 2013-08-30 CN CN201710300645.0A patent/CN107308164A/en active Pending
- 2013-08-30 HU HUE13835019A patent/HUE056646T2/en unknown
- 2013-08-30 DK DK13835019.4T patent/DK2892535T3/en active
-
2016
- 2016-10-13 AU AU2016244279A patent/AU2016244279B2/en active Active
-
2017
- 2017-04-05 US US15/479,663 patent/US20170202842A1/en not_active Abandoned
- 2017-11-10 JP JP2017216933A patent/JP6511117B2/en active Active
-
2018
- 2018-08-07 US US16/056,702 patent/US20180338979A1/en not_active Abandoned
-
2019
- 2019-04-05 JP JP2019072361A patent/JP6684941B2/en active Active
- 2019-10-28 US US16/664,978 patent/US10869869B2/en active Active
-
2020
- 2020-11-11 US US17/095,200 patent/US20210060021A1/en not_active Abandoned
-
2021
- 2021-12-15 CY CY20211101105T patent/CY1124812T1/en unknown
-
2022
- 2022-12-07 US US18/062,764 patent/US20230330091A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015KN00449A (en) | ||
| MX2020004023A (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia. | |
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| MX377157B (en) | PREPARATION FOR USE IN THE TREATMENT OF GD2 POSITIVE CANCER. | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX373851B (en) | METHODS OF ADMINISTRATION OF PIRFENIDONE TREATMENT. | |
| MX2015012866A (en) | Pyridazinone compounds and methods for the treatment of cystic fibrosis. | |
| MX356728B (en) | Pharmaceutical combination for use in the treatment of diabetes type 2. | |
| NZ603319A (en) | Diabetes therapy | |
| PH12015500954A1 (en) | Device for extracorporeal blood treatment | |
| PH12012501719A1 (en) | Compounds for immunoproteasome inhibition | |
| MX362550B (en) | Heterocyclic inhibitors of glutaminase. | |
| MY185206A (en) | Therapeutically active compounds and their methods of use | |
| EA033067B1 (en) | Method for treating metabolic disorders in a patient having a contraindication for a biguanide compound | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| EP3141603A4 (en) | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective | |
| MX343968B (en) | Proteasome inhibitor delanzomib for use in the treatment of lupus. | |
| MX356317B (en) | Treatment of symptoms associated with female gastroparesis. | |
| PH12014502065A1 (en) | Vesicular formulations | |
| MX369774B (en) | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders. | |
| MX2021014120A (en) | Treatment of androgen deprivation therapy associated symptoms. | |
| MX2018011607A (en) | Sultiame for the treatment of sleep apnea. | |
| TN2013000336A1 (en) | 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. | |
| GEP20196947B (en) | Bremelanotide therapy for female sexual dysfunction |